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Transitional changes in the incidence of osteonecrosis in systemic 
lupus erythematosus patients: focus on immunosuppressant 
agents and glucocorticoids 
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Transitional changes in the incidence of osteonecrosis in systemic lupus erythematosus 
patients: focus on immunosuppressant agents and glucocorticoids 
  
Abstract 
Objective: The purpose of this study was to investigate transitional changes in the incidence 
of glucocorticoid-associated osteonecrosis in SLE patients, with a focus on 
immunosuppressive agent and glucocorticoid consumption. 
Methods: We retrospectively registered 185 SLE patients with 740 joints, who were newly 
diagnosed and hospitalized for initial high-dose glucocorticoid therapy from 1986 to 2015. 
Immunosuppressive agent, glucocorticoid dose, age, sex, organ lesion at hospitalization, 
complement (C3, C4, CH50) and anti-DNA antibody before initial glucocorticoid therapy, 
the frequency of use of anticoagulant and antilipidemic drugs, and incidence of osteonecrosis 
were documented. 
Results: Based on trends in immunosuppressive agent use, 116 patients treated from 1986 to 
1999, before calcineurin inhibitors were introduced, comprised the past group, and 69 
patients treated from 2000 to 2015 comprised the recent group. Patient characteristics (age, 
sex and organ lesion at hospitalization, complement, anti-DNA antibody, the frequency of use 
of anticoagulant and antilipidemic drugs) were similar between groups. Glucocorticoid doses 
were significantly lower in the recent group than in the past group (highest daily 
glucocorticoid dose, 45.7 vs 59.0 mg/day, respectively; dose per weight, 0.88 vs 
1.16mg/day/kg, respectively; and cumulative dose at 3 months, 3118 vs 3985mg). The 
incidence of osteonecrosis was significantly lower in the recent group than in the past group 
(26.4 vs 41.0%, respectively), particularly in the knee (25.4 vs 46.6%, respectively). 
Conclusion: The incidence of glucocorticoid-associated osteonecrosis in SLE patients 
decreased in association with a decrease in glucocorticoid administration after introduction of 
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immunosuppressant agents. 
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Introduction 
 Multifocal osteonecrosis is a well-known complication in patients who undergo systemic 
glucocorticoid therapy. This glucocorticoid-associated osteonecrosis is presumed to arise 
from circulatory impairment to the epiphysis [1], osteocyte apoptosis and death [2], although 
the exact pathogenesis is currently unclear. Among patients with a history of systemic 
glucocorticoid administration, SLE was reported most frequently [3]. Oinuma et al. [4] 
reported a 44% incidence of osteonecrosis in adult patients with SLE. 
 MRI is a non-invasive diagnostic tool that enables osteonecrosis to be detected much 
earlier and with greater sensitivity and specificity than simple X-ray and bone scintigraphy 
[5]. Although it is asymptomatic at the time of osteonecrosis development, MRI can visualize 
the osteonecrosis with low intensity band in the T1 image during the early phase of up to 3 
months after glucocorticoids start [6]. Gradually, the necrotic area becomes mechanically 
vulnerable, and when it collapses, it causes pain. In other words, there is a time lag from 
development of osteonecrosis to symptomatic onset by collapse of the femoral head. At the 
time of collapse, MRI shows diffuse bone marrow edema with low intensity in the T1 image 
and high intensity in the short tau inversion recovery sequence (or STIR) image [7]. MRI 
screening of osteonecrosis is important because incidence of osteonecrosis is frequent after 
high-dose glucocorticoids therapy and surgical treatment is often required [8]. Sakamoto [9] 
revealed that the incidence of osteonecrosis was highest in the hip (63%), followed by the 
knee (51%), ankle (16%) and shoulder joints (16%), while the incidence of osteonecrosis in 
the ankle and shoulder was 0% in a patient without osteonecrosis in the hips or knees. 
Nakamura et al. [10] observed no new lesions in the first year following initiation of 
glucocorticoid administration in SLE patients who received low-dose glucocorticoids for 
more than a decade; delayed osteonecrosis occurred in only one patient, who experienced an 
SLE recurrence. These results suggest that MRI of bilateral hip and knee joints is a sufficient 
4 
 
screening method for osteonecrosis during the first year of glucocorticoid therapy. 
 Recently, immunosuppressive regimens for renal allografts have improved, resulting in a 
decreased incidence of osteonecrosis, presumably due to reduced glucocorticoid doses [11, 
12]. However, it is unclear whether these improved immunosuppressive regimens would lead 
to a similar decrease in the incidence of osteonecrosis in patients with autoimmune diseases. 
The purpose of this study was to clarify temporal trends in the incidence of osteonecrosis in 
SLE patients, with a focus on immuno- suppressant agent and glucocorticoid consumption. 
 
Material and Methods 
 The research protocol of this retrospective observational cohort study was approved by the 
Research Ethics Committees of the Graduate School of Medicine, Chiba University Board in 
compliance with the Helsinki Declaration. The participants were informed by bulletin board. 
We retrospectively studied 238 SLE patients who received glucocorticoid therapy from 
1986 to 2015. The inclusion criteria were: fulfillment of the ACR 1982 revised criteria for the 
classification of SLE [13]; newly diagnosed SLE managed by hospitalization and 
administration of initial glucocorticoid therapy; and MRI screening of hips and knees during 
the first year following initial glucocorticoid administration. Eighteen patients who were 
previously diagnosed with SLE and were hospitalized for recurrence and 35 patients who did 
not undergo MRI screening were excluded. The remaining 185 patients with 740 joints 
comprised the study group for subsequent analyses. 
Trends in immunosuppressive agent and glucocorticoid consumption were surveyed. 
Survey items concerned the use of intermittent pulse intravenous CYC therapy, calcineurin 
inhibitors (ciclosporin or tacrolimus) and glucocorticoid usage (steroid pulse therapy and 
highest daily glucocorticoid dose per oral dose) that were administered at the time of initial 
admission. Calcineurin inhibitors were introduced in 2000. As a policy of rheumatologists in 
our hospital, immunosuppressive drugs have been intention- ally prescribed to reduce the 
amount of steroid use. Therefore, patients were divided into two groups: the past group 
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(1986-99) and the recent group (2000-15). Our indication of hospitalization depends on the 
severity of organ lesions and the treatment strategy for SLE was consistent throughout the 
study period. 
 
Incidence of osteonecrosis 
 The diagnosis of osteonecrosis was based on the 2001 revised criteria for classification of 
osteonecrosis of the femoral head from the Japanese Ministry of Health, Labor and Welfare 
[14]. Osteonecrosis of the knee was diagnosed in the same manner as the femoral head. The 
incidence of osteonecrosis and the extent of the necrotic area in the femoral head by using the 
type classification [14] was compared between the past and recent groups. Type classification 
is as follows; type A—lesion occupies the medial one-third or less of the weight-bearing 
portion; type B—lesion occupies the medial two-thirds or less of the weight-bearing portion; 
type C1—lesion occupies more than the medial two-thirds of the weight-bearing portion but 
does not extend laterally to the acetabular edge; and type C2—lesion extends laterally to the 
acetabular edge. 
 
Risk factors for osteonecrosis 
Age at initial glucocorticoid therapy, sex, complement (C3, C4, CH50) and anti-DNA 
antibody before initial glucocorticoid therapy, the organ lesion at hospitalization (be- cause 
each patient had a variety of symptoms, we counted them in duplicate) were compared 
between the past and recent groups. The highest daily glucocorticoid dose (mg/day) and the 
highest daily glucocorticoid dose per weight (mg/day/kg), and cumulative dose at 3 months 
(mg) were compared. Glucocorticoid doses were con- verted into equivalent prednisone doses 
based upon the method of Felson and Anderson [15]. Furthermore, anti- coagulants and 
antilipidemic drugs were compared during the first 3 months after glucocorticoid therapy. 
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Statistical analysis 
 JMP Pro 12.0 (SAS, Cary, NC, USA) was used for contingency table analysis with 
Pearson’s Chi-square tests, and comparisons of unpaired groups with the Mann Whitney U 
test. Multivariate logistic regression analysis was calculated for osteonecrosis development as 
a dependent variable with treatment methods (intravenous CYC therapy, calcineurin 
inhibitors, steroid pulse and highest daily glucocorticoid dose) as independent variables. P< 
0.05 was considered significant. 
 
Results 
 Trends in immunosuppressive agent and glucocorticoid consumption are shown in Fig. 1. 
Characteristics of patients in the past and recent periods were similar in terms of clinical 
manifestations and disease activity (Table 1). 
Glucocorticoid doses were significantly lower in the recent group than in the past group 
(highest daily glucocorticoid dose, 45.7 vs 59.0 mg/day; highest daily glucocorticoid dose per 
weight, 0.88 vs 1.16mg/day/kg; and cumulative dose at 3 months, 3118 vs 3985 mg). 
 The highest daily glucocorticoid dose was significantly lower in the recent period than in 
the past period (45.7 vs 59.0 mg/day, respectively). The highest daily glucocorticoid dose per 
weight was also significantly lower in the recent period than in the past period (0.88 vs 
1.16mg/ day/kg, respectively). 
 The incidence of osteonecrosis was significantly lower in the recent period than in the past 
period (26.3 vs 41.0%, respectively). With respect to osteonecrosis of the knee joint, the 
incidence was also significantly lower in the recent period than in the past period (25.4 vs 
46.6%, respectively). In hip joints, the incidence of osteonecrosis also tended to be lower in 
the recent period than in the past period (27.1 vs 35.3%, respectively), without statistical 
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significance. The extent of osteonecrosis of the fem- oral head showed almost similar 
distribution of the type classification between two groups. 
 In the past period, glucocorticoid doses were significantly lower in the group without 
osteonecrosis than in the group with osteonecrosis (highest daily glucocorticoid dose, 57.2 vs 
60.9 mg/day, P = 0.006; highest daily glucocorticoid dose per weight, 1.12 vs 1.22mg/day/kg, 
P = 0.001), except cumulative dose at 3 months (3928 vs 4031 mg, P = 0.90). However, in the 
recent period, glucocorticoid doses were similar between the groups without osteonecrosis 
and with osteonecrosis (highest daily glucocorticoid dose, 47.5 vs 46.9 mg/day, P = 0.65; 
highest daily glucocorticoid dose per weight, 0.90 vs 0.91 mg/ day/kg, P = 0.93; and 
cumulative dose at 3 months, 3081 vs 3186 mg, P = 0.21). The use of anticoagulants was not 
significantly different in the past and recent periods [83% (39 of 47 patients) vs 72% (50 of 
69 patients), P = 0.18]. The use of antilipidaemics was not significantly different in the past 
and recent periods, either [53% (37 of 70 patients) vs 39% (27 of 69 patients), P = 0.10]. 
 Logistic regression analysis showed that only highest daily glucocorticoid dose was 
significantly related to occurrence of osteonecrosis (odds ratio: 1.05/1 mg/day in- crease, 
95% CI: 1.01, 1.07, P = 0.007). 
 
Discussion 
To our knowledge, this is first study to investigate transitional changes in the incidence of 
glucocorticoid-induced osteonecrosis in SLE patients focusing on immunosuppressant drugs 
and glucocorticoids. Glucocorticoid ad- ministration and the incidence of osteonecrosis were 
significantly decreased following the introduction of calcineurin inhibitors (tacrolimus and 
CSA) in 2000. We suggest that these improved immunosuppressive regimens have reduced 
the demand for corticosteroids, and we hypothesize that reduction of corticosteroid doses will 
further decrease the incidence of osteonecrosis. At the same time, rheumatologists should still 
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pay attention to the fact that the incidence of osteonecrosis remains high, at about 26%, after 
initial corticosteroid therapy. 
 Many studies have examined the relationship between glucocorticoid administration and 
osteonecrosis in renal allografts [11, 12], but the association between glucocorticoid dosage 
itself and osteonecrosis remains controversial. Sakai et al. [11] reported that 16% of renal 
allograft patients treated with ciclosporin developed osteonecrosis, whereas none of the 
patients who received tacrolimus had osteonecrosis, suggesting that tacrolimus might be 
associated with a lower incidence of osteonecrosis com- pared with ciclosporin. Takao et al. 
[12] observed a lower incidence of osteonecrosis of the hip and knee (4.7%) in renal allograft 
recipients treated with improved immuno- suppressive regimens (ciclosporin or tacrolimus), 
which reduced cumulative glucocorticoid doses. However, no reports have been published 
about trends in the association between immunosuppressive agents/glucocorticoids and 
osteonecrosis in autoimmune disease. 
New treatment strategies for SLE are currently being evaluated. Based on evidence, MMF 
is recommended as a first-line drug for both remission induction and maintenance therapy of 
active LN by ACR guidelines for screening, case definition, treatment and management of 
LN [16]. The multi-target therapy with MMF, steroids and tacrolimus has been proposed for 
active LN [17]. As adjunctive treatments, HCQ is recommended for all SLE patients with 
nephritis, unless there is a contra-indication [18]. MMF sup- presses lymphocyte proliferation 
in vivo, and HCQ inhibits IFN-a production [19]. These new therapies might further reduce 
the dependence of SLE patients on glucocorticoids, thereby decreasing the risk of 
osteonecrosis. 
This study had several limitations. First, due to its retrospective nature, the 
immunosuppressive regimens used reflected physician preference and were not uniform. 
Calcineurin inhibitor use increased after 2000; to address this, patients were divided into two 
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cohorts depending on whether they were treated before 2000 (past) or from 2000 onwards 
(recent). Second, we documented the extent of necrotic areas, but could not follow up the 
patients. Improved immunosuppressive regimens would be expected to reduce the collapse of 
osteonecrosis and long-term outcome. Third, we only registered inpatients, but not 
outpatients, to limit the analysis to SLE patients who received high-dose glucocorticoid 
therapy. The treatment strategy of SLE in our hospital has not changed during the research 
period. Slight SLE patients, with a skin lesion but without a serious organ lesion or a joint 
lesion, were treated in an outpatient clinic. Such patients were not routinely screened with 
MRI because the amount of glucocorticoid was small and the risk of osteonecrosis deemed to 
be low. Thus, the precise occurrence of osteonecrosis could not be ascertained. However, the 
characteristics of the two cohorts of the past and the recent groups were similar in terms of 
clinical manifestations and disease activity; therefore, we believe that it does not have a big 
influence on this research. Fourth, the pathogenesis of osteonecrosis itself has not yet been 
elucidated. Some patients do not develop osteonecrosis even with same regimen of high-dose 
glucocorticoid therapy [10], although generally the incidence of osteonecrosis gradually 
increases with increasing glucocorticoid dose and gradually decreases with decreasing 
glucocorticoid dose [3]. Therefore, the association between glucocorticoid dose and 
osteonecrosis may be a stochastic and not a deterministic effect. Gene polymorphism may 
play a role in steroid sensitivity [20]. The prophylaxis for steroid-associated osteonecrosis has 
not yet been established, and further study of this condition is needed. 
In conclusion, the incidence of glucocorticoid-associated osteonecrosis in SLE patients has 
decreased in association with decreased glucocorticoid administration following the 
introduction of immunosuppressant agents. 
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Table 1. Comparison between the past and recent groups. 
         Period  Past (1986-1999) Recent (2000-2015) P-value 
         Patients    n=116 n=69  
Age at initial GC, years (range) 31.8 (15-59) 33.0 (15-66) 0.63a 
Female, n (%) 112 (96.6) 58 (84.1) 0.25b 
Organ lesion at hospitalization,  
n (%)c 
   
    Skin disease 22 (19.0) 12 (17.4) 0.82b 
    Arthritis 40 (34.5) 26 (37.7) 0.61b 
    Serositis 11 (9.5) 12 (17.4) 0.11b 
    Renal failure 25 (21.6) 26 (37.7) 0.02b 
    NPSLE 6 (5.2) 6 (8.7) 0.35b 
    Hematologic disorder 28 (24.1) 24 (34.8) 0.12b 
    Other 10 (8.6) 8 (11.6) 0.73b 
Complement and antibody    
    C3, mg/dl (range) 
    C4, mg/dl (range) 
    CH50, U/ml (range) 
    Anti-DNA antibody IU/ml 
42.9 (6-128) 
11.4 (1-60) 
21.5 (1.6-50) 
204.2 (2.5-2710) 
49.4 (12-156) 
10.5 (1-50) 
20.8 (5-67) 
210.5 (2-1242) 
0.09a 
0.06a 
0.28a 
0.49a 
Dose of steroids     
   Highest daily GC dose, mg/day 59.0 (20-80) 45.7 (10-80) <0.001a 
   Highest daily GC dose per weight   
                  mg/day/kg  
1.16 (0.40-2.00) 0.88 (0.25-1.80) <0.001a 
   Cumulative dose at 3 months, mg  3985 (1420-6690) 3118 (1680-6992) <0.001a 
Joints n=464 n=276  
   No. of hips  
   with osteonecrosis, n (%) 
82 (35.3) 38 (27.5) 0.12b 
   No. of knees  
   with osteonecrosis, n (%) 
108 (46.6) 35 (25.4) <0.001b 
   Overall osteonecrosis, n (%) 190 (41.0) 73 (26.4) <0.001b 
Type classification of hip ON n=82 n=38  
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   Type A,  n (%) 
   Type B,  n (%) 
   Type C1,  n (%) 
   Type C2,  n (%) 
4 (5) 
7 (9) 
23 (28) 
45 (59) 
1 (3) 
3 (8) 
9 (24) 
25 (66) 
0.86b 
 
Organ lesion at hospitalization means clinical manifestations in the SLE cohorts. 
GC: glucocorticoid, NPSLE: neuropsychiatric SLE, ON: osteonecrosis 
aMann-Whitney’s U test, bPearson's χ2 test, cOrgan lesion at hospitalization was recorded 
twice for all SLE patients. 
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Figure legend 
Figure 1. Calcineurin inhibitors (CN) were introduced in 2000. Steroid pulse therapy (Pulse) 
was often administered in the early 1990s, but its use gradually decreased thereafter, with a 
peak in 1994. In 1986, the highest daily glucocorticoid dose per oral dose (PSL) was  60 
mg/day, but it gradually decreased to 40 mg/day by 2015. Intermittent pulse intravenous 
CYC therapy was used constantly throughout the study period. The left vertical axis indicates 
the number of patients, while the right vertical axis indicates glucocorticoid dose. The 
horizontal axis shows years. 
 
Figure 
Figure 1. Trends in immunosuppressive agent and glucocorticoid consumption. 
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